Akademik Veri Yönetim Sistemi
Molecular Imaging and Radionuclide Therapy, cilt.33, sa.1, ss.11-18, 2024 (ESCI)
Objectives: This retrospective study aimed to evaluate the prognostic importance of18F-fluorodeoxyglucose (18F-FDG)-positive pelvic lymph nodes (LNs) and extra-pelvic disease on staging18F-FDG positron emission tomography/computed tomography (PET/CT) in patients with bladder cancer. Methods: Bladder cancer patients who underwent staging18F-FDG PET/CT were included in the study. Histopathologic features of tumors, therapy histories, presence of distinguishable tumors on CT and PET images, sizes and maximum standardized uptake value (SUVmax) of primary tumors, total numbers, sizes, and SUVmax of18F-FDG-positive pelvic and extra-pelvic LNs, and total numbers and SUVmax of distant metastases (M1a/1b) were recorded. Patients were followed up until death or the last medical visit. Factors predicting overall survival were determined using Cox regression analysis. Results: Fifty-five patients [median age: 70 (53-84), 48 (87.3%) male, 7 (12.7%) female] with bladder cancer were included in this study. Twenty-nine (52.7%) patients had18F-FDG positive pelvic LNs, while 24 (43.7%) patients had18F-FDG positive extra-pelvic disease. Patients with18F-FDG-positive pelvic LNs had a higher rate of extra-pelvic disease (p=0.003). The median follow-up duration was 13.5 months. The median overall survival was 16.3 months [95% confidence interval (CI) 8.9-23.7]. The primary tumor distinguishability on PET (p=0.011) and CT (p=0.009) images, the presence of18F-FDG-positive pelvic LNs (p<0.001) and18F-FDG-positive extra-pelvic disease/distant metastases (M1a/M1b) (p<0.001), and the number of distant metastases (p=0.034) were associated with mortality. The18F-FDG-positive extra-pelvic disease/distant metastases [p=0.029, odds ratio: 4.15 (95% CI 1.16-14.86)] was found to be an independent predictor of mortality in patients with bladder cancer. Conclusion: The presence of18F-FDG-positive extra-pelvic disease in pretreatment18F-FDG PET/CT is an important prognostic factor in bladder cancer patients.